Researchers have found that the novel anti–interleukin 17 neutralizing monoclonal antibody (Ab-IPL–IL-17) may be effective in patients with rheumatoid arthritis and inflammatory bowel disease (IBD), according to a novel study published by Saviano et al in the Annals of the Rheumatic Diseases. In a preclinical, in vitro study, researchers demonstrated that Ab-IPL–IL-17 was capable of reversing the proinflammatory and promigratory actions of IL-17A and IL-17A/F heterodimers. Further, the novel agent had less off-target effects compared with secukinumab, the current standard of care, and was effective in improving clinical signs of arthritis and neutralizing elevated levels of IL-17 in the serum of patients with IBD compared with reference anti–IL-17 antibodies. The researchers hope to further evaluate the clinical efficacy of Ab-IPL–IL-17 in larger-scale studies.
August 24, 2023